BEIGENE, LTD. (NASDAQ:BGNE) Files An 8-K Other Events

16

BEIGENE, LTD. (NASDAQ:BGNE) Files An 8-K Other Events
Item 8.01. Other Events.

On April 16, 2018, BeiGene, Ltd. (the "Company") issued a press release announcing that the first patient was dosed in a global Phase 2 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, in patients with relapsed or refractory mature T- and natural killer (NK)-cell lymphomas. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On April 16, 2018, the Company issued a press release announcing that preliminary clinical data from an ongoing Phase 1 trial of its investigational PARP inhibitor pamiparib in Chinese patients with locally advanced or metastatic high-grade non-mucinous ovarian cancer, including fallopian cancer, or triple-negative breast cancer, who had disease progression following at least one line of chemotherapy were presented at the 2018 American Association for Cancer Research (AACR) Annual Meeting, being held in Chicago. The full text of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit Index


BeiGene, Ltd. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingExhibit 99.1BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab  in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas CAMBRIDGE,…
To view the full exhibit click here

About BEIGENE, LTD. (NASDAQ:BGNE)

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.

An ad to help with our costs